Palantir shares rise 5% premarket as AI-fueled demand powers annual guidance raise
Investing.com - H.C. Wainwright raised its price target on Senseonics Holdings (NYSE:SENS) to $1.40 from $1.10 on Tuesday, while maintaining a Buy rating on the diabetes technology company. Currently trading at $0.49, SENS has analyst targets ranging from $1.10 to $2.00, with InvestingPro data showing 2 analysts recently revising earnings estimates upward.
The revised target follows Senseonics’ analyst event at the 2025 American Diabetes Association annual meeting in June, where the company outlined plans to increase its Eversense patient base from approximately 13,000 in 2025 to over 50,000 by 2027. With a current market capitalization of $395.8 million and an overall Financial Health score of FAIR according to InvestingPro, the company maintains strong liquidity with a current ratio of 6.88.
H.C. Wainwright identified four key growth drivers: the approval and launch of Eversense 365 in the EU expected in the second half of 2025; the launch of Eversense pairing with Sequel Diabetes twiist insulin delivery system also expected in the second half of 2025; the launch of the Gemini system expected in the second half of 2026; and the launch of the Freedom system expected in 2027.
The research firm has updated its financial model to reflect these growth expectations, now forecasting total revenues of $75.6 million in 2026, up from a previous estimate of $59.7 million, and $118.4 million in 2027, revised from $94.6 million.
Senseonics management believes the company could reach operational break-even by the end of 2027 if its growth trajectory remains on track.
In other recent news, Senseonics Holdings reported mixed financial results for the first quarter of 2025. The company achieved an earnings per share of -$0.02, which was better than the expected -$0.03, but fell short of revenue forecasts, bringing in $6.3 million compared to the anticipated $6.92 million. Despite the revenue miss, Senseonics demonstrated a 24% year-over-year growth in net revenue. Additionally, the company reduced its debt to $35.3 million, strengthening its financial position.
In a strategic move, Senseonics initiated a public stock offering and a private placement, with Abbott Laboratories (NYSE:ABT) agreeing to purchase up to $25 million in common stock. The proceeds are earmarked for launching Eversense 365 and other corporate purposes. Analysts at H.C. Wainwright have assumed a Buy rating for Senseonics, with a price target of $1.10, citing the company’s unique market position. These developments highlight the company’s ongoing efforts to expand its market presence and enhance its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.